Documente Academic
Documente Profesional
Documente Cultură
Pharmaceuticals
•The pharmaceutical industry is one of the vital and distinct industries as it deals
with the lives of the people. At present, pharmaceutical drugs are the most
preferred therapeutic treatments for the global population of 6.45 billion.
•The coverage of the market is on the basis of therapeutic segment to which the
drugs belong.
•All figures in Major Markets and Major Players are converted to USD with
conversion rates as on December 31 of the respective years.
• HIGHLIGHTS
• INDUSTRY OVERVIEW
• GROWTH DRIVERS
• TECHNOLOGY
• MAJOR MARKETS
• MAJOR PLAYERS
• REGULATORY ASPECTS
• FUTURE OUTLOOK
HIGHLIGHTS
•In 2005, the three major markets – North America, Europe and Japan – were
valued at USD491.22 billion, accounting for 84.30% of the global pharmaceutical
market
•Asia, Africa and Australian market value in 2005 was USD40.86 billion and has
grown by 2.14% compared with 2004
HIGHLIGHTS
•Cardiovascular was the largest therapeutic segment with the sales value of USD79.03
billion in 2005, growing by 3% compared with 2004
•Cholesterol and triglycerides lowering class is the largest therapeutic class of the
cardiovascular segment with the sales value of USD31.60 billion in 2005 and accounted
for 5.42% of the total pharmaceutical market
•The top 10 therapeutic classes contributed USD177.60 billion, accounting for 30.47% of
the total pharmaceutical market.
•The top 10 best-selling drugs accounted for USD53.2 billion, contributing about 9.13% of
the total pharmaceutical market.
•Lipitor, with a sale of USD12.19 billion, was the largest selling blockbuster drug in 2005
and accounted for 2.09% of the global pharmaceutical market
•The recent product withdrawals including Tysabri in 2005, and Vioxx and Bextra in 2004
have affected the image of the pharmaceutical industry. This in turn has led the FDA to
focus more on safety issues prior to drug approval.
HIGHLIGHTS
•The number of new drugs approved in the US by the FDA decreased by 53% to 17 in 2005
from 36 in 2004. Drugs worth USD21.2 billion are estimated to lose their patent rights in
2006, which is an increase of 76% compared with 2005
•On an average, the value of the M&A in the last 10 years was more than USD40 billion. The
number of M&A deals in 2005 was 247 and the total deal value was USD68.20 billion. The
deal number has seen a decline of 8% compared with 2004
•The top 10 global pharmaceutical companies spent USD45.79 billion on R&D in 2005. The
amount spent on consumer advertising of prescription and non-branded drugs was USD4.51
billion in 2004
•The pharmaceutical industry is complex, dynamic and highly globalized with many
companies operating as multinationals in various countries. The geographical boundaries
are blurring in the pharmaceutical industry with more than one country involved in the
manufacture of a single finished product.
Global Pharmaceutical Market Size and Growth Rate (2000 -2005)
USDbn
6%
200
•The market grew at an annual rate of
4%
100 2%
0 0%
5.95% over the previous year; it is the 2000 2001 2002 2003 2004 2005
Industry Size (LHS) Growth Rate ( RHS)
lowest growth rate in the last five years. Source: IMS world Reviews and Cygnus Research
The global pharmaceutical market is valued at USD582.71billion in 2005 and grew by 5.95%
over that of in 2004.
INDUSTRY OVERVIEW
5.31% 5.37%
regions has increased from Market size in 2000: USD352.19bn
7.01%
Market size in 2005: USD582.71 bn
3.29%
North America, the largest pharmaceutical market accounted for 43.04% of the global
pharmaceutical market in 2005 with sales of USD262.43 billion.
INDUSTRY OVERVIEW
1 Cholesterol. & Triglyceride 26.1Cholesterol & Triglyceride 30.2Cholesterol & Triglyceride 31.6
reducers Reducers reducers
2 Anti-ulcerants 24.3Antiulcerants 25.5Anticancer* 26.6
3 Anti-depressants 19.5Anticancer 23.8Antiulcerants 26.3
4 Anti-rheumatic non-steroidals 12.4Antidepressants 20.3Antidepressants 20.1
The top 10 best selling drugs during 2005 accounted for USD53.2 billion and constituted about 9.13%
of the total pharmaceutical market. Among the top 10 drugs, Diovan/Co-Diovan – a
hypertensive drug – recorded a higher growth of 19.62% y/y with sales of USD3.70 billion
INDUSTRY OVERVIEW
•The likely shift in the disease pattern from communicable to non-communicable diseases
would mainly drive the pharmaceutical industry in the future. The DALYs due to non-
communicable diseases has been projected to increase from 47% in 2002 to 57% in 2030. This
significant increase is being fuelled by the growth in aging population and changes in life style,
which includes poor eating habits, less physical exercise, and a stressful work atmosphere
(WHO, 2005).
•The increase in Healthcare expenditure across the globe owing to rapid advances in medical
technologies, population ageing and higher quality expectations from the public would drive
the demand for the pharmaceuticals. The growth in pharmaceutical spending is more than that
of the total healthcare spending of the OECD countries in the last few years.
•Biotechnology based drugs are major contributors in the new product sales growth and
accounted for 27% of the overall products in R&D pipeline in 2004. The new technologies will
accelerate the development of biotech drugs in the future. Though biotech products accounted
for 8-10% of the total pharmaceutical market in 2004, this proportion is expected to increase in
future (IMS, 2004) backed by a robust R&D pipeline.
•Technology has been making dramatic changes at the drug development level, enabling an
analysis of 100,000 compounds per day using combinatorial chemistry and high throughput
screening. Technologies like medical imaging and pharmacogenomics are shortening the
development timelines and the costs along with the increase in the effectiveness of the drug.
Rising healthcare expenditures and the life style based diseases are the major drivers of the global
pharmaceutical industry.
ISSUES & CHALLENGES
USDbn
30
20
20
drug approvals has become one of the major issues being 10 10
2004. After the Vioxx withdrawal issue came into Number of new drugs approved (LHS)
Source:Source:
PhRMA, Cygnus
PhRMAResearch
limelight, the USFDA is focusing more on safety of the and FDA
Increase in Research & Development spending by the pharmaceutical companies are not
turning out towards higher drug approvals
ISSUES & CHALLENGES
•The returns on the promotions spent by the pharmaceutical companies are not
proportionate to the amount spent on promotions. This is exerting considerable pressure
on the pharmaceutical firms to get maximum returns from their increased marketing
expenditures, for which they have to identify the poorly performing markets, ineffective
promotional campaigns and make corrective measures to maximize the amount spent on
promotions.
•Parallel trade has a significant negative impact on the R&D investment and size of the
work force of research-based pharmaceutical companies in Europe. Within the European
Union, parallel trade was estimated at USD3.3 billion in 2001 and projected to reach
USD7.4 billion in 2006.
To curtail the healthcare budgets, governments across the globe are encouraging the use
of generic medicines and even are reducing the prices of the generics regularly.
TECHNOLOGY
Process Analytical Technology would be made mandatory in the years to come by the
regulators globally because of its inherent advantages in control of the operations.
TECHNOLOGY
New technologies
•Super computers in drug discovery
Microdosing of new experimental drugs to human volunteers helps to determine the key pharmacokinetic
data before phase-I clinical trial and save considerable amount of money. Determination of
pharmacokinetic data of a new compound by microdosing takes 4-6 months and costs USD0.35m. It is an
improvement over the conventional phase-I studies which take 12-18 months, costing USD3-5m for the
determination of the same data (Bryan, 2005b). In the microdosing technique, volunteers are given radio-
labeled doses of new experimental drugs and accelerator mass spectroscopy (AMS) is used to count
radioactive carbon atoms in blood, urine and fecal samples taken from the volunteers.
•Polymorph screening
ReactArray Solo, a new polymorph screening technology from Anachem Ltd, the UK-based instrumentation
company, launched in February 2006, provides fast and efficient polymorph screening by enabling
simultaneous runs of up to 48 different reaction conditions. This technology will benefit the research-
based pharmaceutical companies to a greater extent by protecting the patents of their novel drugs.
Polymorph screening would be a major technology in the years to come as the protection of the
intellectual property rights would be very crucial for the research based pharmaceutical
companies in the scenario of the lower drug approval rates.
MAJOR MARKETS
(Medical News Today, January 11, 2006). US Europe others Japan UK China Mexico Brazil
USDbn
200
lowest in the last five years. This is due to 150 10%
%
100
the increased competition from the generic 50
5%
(Vioxx and Bextra) from the market. Market Size (LHS) Growth Rate (RHS)
Between 2001 and 2005, the CAGR was Source: Cygnus Research
9.9%.
The US is the largest pharmaceutical market globally with the total sales of USD248 billion in
2005 with the growth rate of 7.83%.
MAJOR MARKETS
in 2005 has largely been offset by the higher Source: Cygnus Research
sales of Seroquel, wellbutrin, Cymbalta and
Pharmaceutical market share by value in the US, 2005
Risperdal of CNS segment.
10.97%
8.02%
5.20%
3.39% 3.51% 4.44% 4.80% 4.96%
•Pfizer, the largest company, accounted for Pfizer
Merck & Co
GlaxoSmithkline
Astrazeneca
Johnson & Johnson
Novartis
10.97% of the market during the year with Amgen
Bristol Myers Squibb
Sanofi-Aventis
Others
Lilly
Drugs related to the Central Nervous System are the largest therapeutic segment in the US
with total sales of USD42.45 billion.
MAJOR MARKETS
USDbn
30 0%
20
-5%
•The growth rate is the lowest in the last three 10
0 -10%
years but is better than the negative growth 2001 2002 2003 2004 2005
rates seen in 2001 and 2002 owing to the Market Size (LHS) Growth Rate (RHS)
economic recession, and was above the 2001- Source: Cygnus Research
2005 CAGR of 5.75%.
Pharmaceutical market segmentation in Japan, 2005
billion in 2005 and accounts for about 21.84% ofSource: Cygnus Research
the total pharmaceutical market.
Pharmaceutical sales in Japan in 2005 is USD59.53billion and the drugs related to
cardiovascular disorders are the largest selling drugs
MAJOR MARKETS
the UK) has grown by 9.86% y/y in 2005 with the 150
30%
25%
USDbn
total sales of USD149.26 billion. 100
20%
15%
50 10%
• This is the second year of the continuous 5%
0 0%
decline in growth rate in the last five years, 2001 2002 2003 2004 2005
which has seen a CAGR of 19.29%. It is mainly a Market Size(LHS) Growth Rate(RHS)
result of market loss owing to the parallel trade Source: Cygnus Research
estimated to the extent of USD5 billion in 2005
Major Pharmaceutical markets in Europe, 2005
(IMS, 2005). Germany 32.5
France 31
Italy 19.6
Pharmaceutical market size in Europe (excluding UK) in 2005 is USD149.26 billion and
Germany is the leading pharmaceutical market in the region with sales of USD32.5 billion
MAJOR MARKETS
The UK
Pharmaceutical market in the UK (2001-05)
•The pharmaceutical market in the UK has 25 18%
USDbn
12%
15
Pharmaceutical sales in the UK market is valued at USD20 billion in 2005 with the
cardiovascular as the leading therapeutic segment in 2005.
MAJOR MARKETS
USDbn
30%
6
total sales of USD9.7 billion. The 2000-2005 20%
4
CAGR was 15.23%. 2 10%
0 0%
2000 2001 2002 2003 2004 2005
• In conjunction with eased export restrictions Market Size(LHS) Growth Rate(RHS)
and the Mexican governments restrictions of Source: Cygnus Research
manufacturing capacity in the country has led
to huge market growth with increased exports Pharmaceutical market segmentation in Mexico, 2005
The pharmaceutical market in Mexico is valued at USD9.7 billion in 2005 and Anti-infective
is the leading therapeutic segment of the market.
MAJOR MARKETS
USDbn
10%
15.24%
raw material requirement of the
pharmaceutical market is imported. 11.54%
7.65%
16.55%
6.24% 9.64%
•Alimentary or metabolism is the leading Cardiovascular Central Nervous System
therapeutic segment in the market with sales of Alimentary/Metabolism Respiratory
Anti-Infectives Dermatologicals
USD1.14 billion, accounting for 16.55% of the Genito-Urinary Cytostatics
Others
market in 2005
Source: Cygnus Research
USDbn
USD11.4 billion in 2005 and has reported a growth 6 15%
•The excellent growth of the market has been driven by an expanding Chinese urban
population, which combined with an increasing standard of living, has created a growing
awareness of the importance of healthcare.
•Nearly 80% of the drugs in the country is distributed through hospitals whereas 15% is sold
through retail outlets and the rest is through convenience stores that mostly sell over-the-
counter drugs (Burril and Co, 2005).
•The major players in the market are JS Yangzijiang Fty, Pfizer, GlaxoSmithKline, Roche,
Fresenius, AstraZeneca, Novartis, HLJ Harbin Pharm, Merck & Co and Johnson & Johnson.
The pharmaceutical market in China is valued at USD11.4 billion in 2005 and about 80% of
the drugs in the market is distributed through the hospitals.
MAJOR PLAYERS
2 Johnson & 50.51 47.35 6.67 10.41 8.51 22.33% 178.78 197.86 -17.12
Johnson
3 GlaxoSmithKline 37.27 38.50 (3.19) 8.28 7.74 6.98% 142.68 281.38 -10.67
4 Sanofi-Aventis 32.34 34.38 (5.93) 7.50 6.85 9.49% 117.51 56.52 -97.21
5 Novartis 32.31 28.24 14.41 6.14 5.60 9.64% 143.77 123.97 51.90
6 Roche 26.99 27.64 (2.35) 5.11 6.24 -18.11% 26.65 21.21 13.77
7 Pfizer is
AstraZeneca the largest company
23.95 in the
21.42 global4.72
11.81 pharmaceutical
3.68 market
28.26% with sales of 59.86
77.27 USD51.2920.41
billion in 2005.
MAJOR PLAYERS
Pfizer Inc
•Pfizer has three business segments: Health care, Animal health and consumer health care.
•Health care constitutes the core of Pfizer Inc and accounted for 86.32% of the total revenue
in 2005.
•Consumer health care segment accounts for 7.56% of the total revenue in 2005.
•Animal health segment accounted for 4.3% of the total revenues in 2005.
Top ten products: Pfizer 2005
Key Financials: Pfizer Inc. 2003 - 2005
S.No. Brand Name Sales in 2005 (USDbn)
Financial Year Ending Dec-05 Dec-04 Dec-03
1Lipitor 12.2
Revenues (USDbn) 51.29 52.51 44.73
2Norvasc 4.7
Marketing & Admin. Expenses 16.99 16.90 15.10
3Zoloft 3.3
(USDbn)
4Celebrex 1.7
R & D expenses (USDbn) 7.44 7.68 7.48
5Viagra 1.6
Net Earnings (USDbn) 8.08 11.36 3.91
6Xalatan/ 1.4
Net EPS (USD) 1.10 1.51 0.54 Xalacom
9Camptosar 0.91
Dividends (USD) 0.76 0.68 0.60
10Genotropin 0.808
Source: Company Website & Annual Reports
Source: Annual Report, 2005
Pfizer’s leading block buster drug Lipitor with sales of USD12.2 billion accounts for 2.09% of
the global pharmaceutical market.
MAJOR PLAYERS
Sanofi-Aventis
•The company has two business segment: pharmaceuticals (principally prescription drugs) and
human vaccines.
Source: Company Website & Annual Report Source: Annual Report, 2005
NA-Not Available
Sanofi-Aventis is the third largest pharmaceutical company (considering only the pharmaceutical
sales)with higher net margins of about 23% in 2005 when compared to other major players
MAJOR PLAYERS
Novartis
•Novartis has three business divisions – Pharmaceuticals, Sandoz (generic pharmaceuticals) and
Consumer Health.
•The sales of Novartis’ Pharmaceutical division increased 10% to USD20.3 billion backed by a
dynamic growth ahead of the market and in all regions.
•Sandoz has reported generic pharmaceutical sales of USD4.7 billion in 2005.
•Consumer Health net sales increased by 8% to USD7.3 billion, bolstered by a double-digit growth
performance in OTC. Top ten products: Sanofi-Aventis 2005
Key Financials: Sanofi-Aventis 2003 - 2005
S.No. Brand Name Sales in 2005 (USDbn)
Financial Year Ending Dec-05 Dec-04 Dec-03
1Lovenox 2.54
2Plavix 2.40
Revenues (USDbn) 32.34 34.38 30.50 3Taxotere 1.91
Marketing & Admin. Expenses 9.77 10.76 9.43 4Eloxatine 1.85
(USDbn)
5Stilnox 1.80
R & D expenses (USDbn) 4.79 5.40 5.10
6Allegra 1.59
Net Earnings (USDbn) 7.50 6.85 5.59
7Lantus 1.44
Net EPS (USD) 5.61 5.14 4.13
8Delix 1.20
Net Margin (%) 23.19 19.92 18.32
9Copaxone 1.07
Op. Income (USDbn) 10.80 10.47 9.10
10Aprovel 1.06
Dividends (USD) NA 1.62 1.28
Source: Annual Report, 2005
Source: Company Website & Annual Report, NA-Not Available
Novartis revenues in 2005 is about 32.34 billion with the major focus into oncology
products.
MAJOR PLAYERS
Roche
•Roche has two business divisions –Pharmaceuticals & Diagnostics.
•Roche Diagnostics has reported sales of USD6.26 billion in 2005 as compared with USD6.91
billion in 2004.
Astra Zeneca
•AstraZeneca has only one business segment: Pharmaceuticals.
•AstraZeneca’s flagship product Nexium sales were up 18% to USD4.63 billion. Sales in the US
were up by 15% to USD3.12 billion, and this strong volume growth continues despite being
partially offset by lower price realization. Nexium sales in other markets have grown by 25%.
Top ten products: AstraZeneca 2005
Key Financials: AstraZeneca 2003 - 2005
S.No. Brand Name Sales in 2005 (USDbn)
Financial Year Ending Dec-05 Dec-04 Dec-03
1 Nexium 4.633
Revenues (USDbn) 23.95 21.42 18.85 2 Seroquel 2.761
Marketing & Admin. 8.69 8.26 7.39 3 Seloken/Toprol-XL 1.735
Expenses (USDbn)
4 Losec/Prilosec 1.652
R & D expenses (USDbn) 3.37 3.46 3.01
5 Crestor 1.268
Source: Company Website & Annual Report Source: Annual Report, 2005
Nexium of Astra Zeneca sales increased in 2005 all across the US and and other regions with
Seroquel following at the seconf bestselling product
MAJOR PLAYERS
Merck
• Revenues of Merc in 2005 dropped marginally to USD22 billion from USD22.9 billion in
2004
• R&D expanses of the company reduced to USD3.84 billion in 2005 from USD4.01 billion in
2004
• Zocor is top product of the company in 2005 posting a total sales of USD4.38 billion
Top ten products: Merck & Co 2005
Key Financials: Merck & Co 2003 - 2005
S.No. Brand Name Sales in 2005
Financial Year Ending Dec-05 Dec-04 Dec-03 (USDbn)
1 Zocor 4.381
Revenues (USDbn) 22.0 22.9 22.48
2 Fosamax 3.191
Marketing & Admin. Expenses 7.15 7.23 6.39
3 Cozaar/Hyzaar 3.037
(USDbn)
4 Singulair 2.975
R & D expenses (USDbn) 3.84 4.01 3.28
5 Proscar 0.741
Net Earnings (USDbn) 4.63 5.81 6.83
6 Primaxin 0.739
Net EPS (USD) 2.10 2.61 3.03
7 Vasotec/Vaseretic 0.623
Net Margin (%) 21.05 25.37 30.38
8 Cosopt/Trusopt 0.617
Op. Income (USDbn) 7.36 7.97 8.42
9 Cancidas 0.57
Dividends (USD) 1.52 1.49 1.45
10 Maxalt 0.348
Source: Company Website & Annual Report
Source: Annual Report, 2005
Merc experiencing a lean result in 2005 in terms of revenues, net return and net margin
although the R&D spending of the company decreased
MAJOR PLAYERS
Bristol Myers Squibb suffers decline of sales in two of its three business divisions-
pharmaceuticals and healthcare
MAJOR PLAYERS
Wyeth
•Wyeth has three divisions: Wyeth Pharmaceuticals, Wyeth Consumer Healthcare, and Fort
Dodge Animal Health.
•Wyeth Pharmaceuticals revenues were increased by 10% to USD15.32 billion in 2005 as
compared with 2004.
•Wyeth Consumer Healthcare has reported sales of USD2.6billion in 2005.
•Animal Health has grown by 5% for the year 2005 to USD0.88 billion compared with 2004.
Top ten products: Wyeth 2005
Key Financials: Wyeth 2003 - 2005
S.No. Brand Name Sales in 2005 (USDbn)
Financial Year Ending Dec-05 Dec-04 Dec-03
1Effexor 3.458
Revenues (USDbn) 18.75 17.35 15.85
2Protonix 1.684
Marketing & Admin. Expenses 6.11 5.80 5.46
(USDbn) 3Prevnar 1.508
R & D expenses (USDbn) 2.74 2.46 2.09 4Enbrel 1.083
Net Earnings (USDbn) 3.65 1.23 2.05 5Nutrition 1.04
Net EPS (USD) 2.73 0.93 1.54 6Premarin 0.908
Net Margin (%) 19.46 7.08 12.93 7Zosyn/Tazocin 0.891
Op. Income (USDbn) 4.78 -0.12 2.36 8Zoton 0.375
Dividends (USD) 0.96 0.92 0.92 9BeneFIX 0.343
Source: Company Website & Annual Report 10Rapamune 0.3
Source: Annual Report, 2005
Wyeth posts growth in its pharmaceuticals and animal health business by 10% and 5%
respectively in 2005
REGULATORY ASPECTS
Regulatory Bodies
Major divisions of FDA
The US
•The Center for Biologics Evaluation and Research
United States Food & Drug administration
•The Center for Devices and Radiological Health
•The Center for Drug Evaluation and Research
European Union
•The Center for Food Safety and Applied Nutrition
•The Center for Veterinary Medicine
The European Medicines Agency (EMEA)
Ministry of Health, Labor & Welfare •Committee for Medicinal Products for Human Use
•Pharmaceutical and Food Safety Bureau office •Committee for Medicinal Products for Veterinary
Use
•Health Policy Bureau •Committee on Orphan Medicinal Products
REGULATORY ASPECTS
The US
USFDA sets up Drug Safety Oversight Board
In line with the regulatory reforms announced by the FDA in the last quarter of 2004, USFDA
set up a Drug Safety Oversight Board (DSB) February 2005 to oversee the management of
drug safety issues and to increase the transparency of approval process and safety of drugs.
USFDA becomes more cautious in approving new drugs amid widespread public outcry against
the approval of high profile drugs
REGULATORY ASPECTS
EU
FDA and EU extend Confidentiality Agreement
The USFDA, the European Commission (EC), and the EMEA extended their confidentiality
agreement on medicinal products for human and veterinary use for five more years. This
agreement, signed in September 2003, was set to expire in 2005. This confidentiality
agreement allows the three agencies to exchange information on legal and regulatory
issues, scientific advice and orphan drug designation, inspection reports, marketing
authorization procedures and post-marketing surveillance.
Japan
Application for approval of generic drugs modified
In September 2005, the MHLW modified the application for the approval of generic drugs
with single active pharmaceutical ingredient. Now, the manufacturers of generic drugs
have to specify in the application, details such as the brand name of the generic drug,
active pharmaceutical ingredient, dosage form, quantity and the company name. The new
additions to the application are ‘the name of the generic company’ and ‘active
pharmaceutical ingredient.’
Generic drug manufacturers in Japan now needs to declare the name of the active
pharmaceutical ingredient
MERGERS & ACQUISTIONS
106
•Need for low cost pharmaceuticals 120
100
USDbn
80 65
•Growing generics market 60 CAGR - 11%
40
Big pharmaceutical firms are acquiring specialty pharmaceutical and biotech firms owing
to decrease in the success rate of their R&D, increase in patent expiries and product
recalls, which are shortening their list of patented drugs and ultimately hitting a large
source of revenue.
MERGERS & ACQUISTIONS
M&A Trends
•Pharmaceutical M&A accounted for more than one-fourth of total healthcare M&A in deal
value
USDbn
246 247 100
250
80 73.38 68.20
200 176
60 40.00
150 37.88
100 40
50 20
0 0
2001 2002 2003 2004 2005 2001 2002 2003 2004 2005
Smooth communication between the partners are important to reap the maximum benefit of
alliances and acquisitions
FUTURE OUTLOOK
•The US would still be the leading market with sales of about USD267-270 billion, with
a growth rate between 8-9% y/y in 2006.
•The higher growth rate in the market is owing to the increased spending on the
prescription drugs with the new Medicare Part D of Medicare Prescription Drug
Program, which has come into effect on January 1, 2006. It provides prescription drug
coverage to more than 40m people of the US.
•The Latin American market is expected to grow at a higher rate of 10%, with
increasing share of healthcare spending as a percentage of GDP in the market and
higher economic growth.
The US is still the leading market in pharmaceuticals with a higher growth rate mainly due to
increased spending on the prescription drugs
FUTURE OUTLOOK
•In the future, an aging global population; the shift in the disease pattern towards lifestyle
disorders; and increase in biotechnology based drugs will continue to be the prime driving factors
of the pharmaceutical industry.
•Increase in number of patent expiries is a growing concern for the major pharmaceutical
companies among the research-based pharmaceutical companies. In 2006 alone, drugs worth
USD21.20 billion are going off-patent.
•Generic variants of five major biopharmaceutical drugs are expected to hit the market in 2006.
Amgen’s anti-anemic drug Epogen, with a global sale of USD2.5 billion in 2005, is one of the major
biopharmaceutical drugs going off-patent in 2006.
Major Pharmaceutical and Biopharmaceutical Drugs Losing Patents in 2006
Pharmaceuticals Biopharmaceuticals
Brand Patent holder Brand Patent holder
•The pharmaceutical industry will witness further consolidation in the future too.
•In February 2006 alone, a total of 16 M&A worth USD965m happened in the industry.
The largest deal for in the first three months of 2006 being Indian-based Dr Reddy’s
Laboratories acquisition of Betapharm Group of Germany for USD570m.
•M&As will be driven mainly by the need to refill drying blockbusters of big
pharmaceutical companies, which will push they into acquiring biopharmaceutical
companies by the need to tap the growing generics market.
•The FDA is concerned more about the safety of the new drugs that comes up for its
approval. In the near future it might mandate the requirement of long-term safety
data for approving the drugs used to treat chronic ailments mandatory.
•In order to improve the manufacturing standards further, the FDA is also expected to
make compliance to process analytical technology mandatory mandatory in the future.
Keeping a healthy product pipeline would be the major concern of the pharmaceutical
companies in the future and this will lead to M&A deals